🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526014-87-00
Completed Phase I

A Phase 1 first-in-human study to evaluate SAR448272 in adult participants

2026-526014-87-00 · tracked via the Priya Life Science EU tracker
Sponsor
Sanofi-Aventis Recherche & Developpement
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
19/06/2026
Enrollment target
147
Sites
Germany

Condition studied

healthy volunteers, immunological diseases

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526014-87-00 on CTIS ↗ ← All trials in the EU